T1	PROC 46 89	Ensayo para evaluar la seguridad y eficacia
T2	CHEM 152 166	antiretroviral
T3	CHEM 96 120	fármaco en investigación
#1	AnnotatorNotes T3	C0013230; Investigational New Drugs; Pharmacologic Substance
T4	PROC 140 166	tratamiento antiretroviral
T5	DISO 187 210	infectadas por el VIH-1
T6	PROC 215 242	tratamiento antirretroviral
#2	AnnotatorNotes T6	C1963724; Antiretroviral therapy; Therapeutic or Preventive Procedure
T7	PROC 268 290	Ensayo clínico fase II
#3	AnnotatorNotes T7	C0282460; Phase 2 Clinical Trials; Research Activity
T8	PROC 296 327	evaluar la seguridad y eficacia
T9	CHEM 331 342	Vedolizumab
#4	AnnotatorNotes T9	C2742797; vedolizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T10	PROC 357 384	tratamiento antirretroviral
#5	AnnotatorNotes T10	C1963724; Antiretroviral therapy; Therapeutic or Preventive Procedure
T11	DISO 434 457	infectadas por el VIH-1
T12	PROC 462 489	tratamiento antirretroviral
#6	AnnotatorNotes T12	C1963724; Antiretroviral therapy; Therapeutic or Preventive Procedure
T13	DISO 539 560	infectados por el VIH
#7	AnnotatorNotes T13	C0458074; Human immunodeficiency virus (HIV) status; Finding
T14	PROC 567 594	tratamiento antirretroviral
#8	AnnotatorNotes T14	C1963724; Antiretroviral therapy; Therapeutic or Preventive Procedure
T15	DISO 645 667	infección por el VIH-1
T16	DISO 694 701	Viremia
#9	AnnotatorNotes T16	C0042749; Viremia; Disease or Syndrome
T17	CHEM 728 731	ARN
#10	AnnotatorNotes T17	C0035668; RNA; Nucleic Acid, Nucleoside, or Nucleotide
T18	ANAT 756 760	CD4+
#11	AnnotatorNotes T18	C0039215; CD4 Positive T Lymphocytes; Cell
T19	PROC 745 760	Niveles de CD4+
#12	AnnotatorNotes T19	C0243009; CD4+ lymphocyte count; Laboratory Procedure
T20	PROC 788 800;811 826	interrupción del tratamiento
#13	AnnotatorNotes T20	C0850893; stop medication; Therapeutic or Preventive Procedure
T21	CHEM 963 971	fármacos
#14	AnnotatorNotes T21	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T22	PROC 830 866	Consentimiento informado por escrito
#15	AnnotatorNotes T22	C0811741; Obtain informed written consent; Health Care Activity
T23	DISO 987 1011	Infecciones oportunistas
#16	AnnotatorNotes T23	C0029118; Opportunistic Infections; Disease or Syndrome
T24	DISO 1035 1086	Co-infección activa por virus B o C de la hepatitis
T25	DISO 1089 1113	infección latente por TB
T26	DISO 1128 1136	Cirrosis
#17	AnnotatorNotes T26	C1623038; Cirrhosis; Disease or Syndrome
T27	DISO 1138 1157	hipertensión portal
#18	AnnotatorNotes T27	C0020541; Portal Hypertension; Disease or Syndrome
T28	DISO 1162 1177	hiperesplenismo
#19	AnnotatorNotes T28	C0020532; Hypersplenism; Disease or Syndrome
T29	DISO 1204 1214	Neoplasias
#20	AnnotatorNotes T29	C0006826; Malignant Neoplasms; Neoplastic Process | C0027651; Neoplasms; Neoplastic Process | C1882062; Neoplastic disease; Neoplastic Process
T30	PROC 1250 1261	tratamiento
#21	AnnotatorNotes T30	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T31	PROC 1298 1311	quimioterapia
#22	AnnotatorNotes T31	C0392920; Chemotherapy Regimen; Therapeutic or Preventive Procedure | C3665472; Chemotherapy; Therapeutic or Preventive Procedure
T32	CHEM 1384 1392	fármacos
#23	AnnotatorNotes T32	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T33	CHEM 1442 1450	fármacos
#24	AnnotatorNotes T33	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T34	CHEM 1546 1556	creatinina
#25	AnnotatorNotes T34	C0010294; creatinine; Biologically Active Substance · Organic Chemical
T35	PROC 1603 1613	vacunación
#26	AnnotatorNotes T35	C0042196; Vaccination; Therapeutic or Preventive Procedure
T36	DISO 1648 1653	gripe
#27	AnnotatorNotes T36	C0021400; Influenza; Disease or Syndrome
T37	DISO 1702 1727	Enfermedad cardiovascular
#28	AnnotatorNotes T37	C0007222; Cardiovascular Diseases; Disease or Syndrome
T38	DISO 1737 1743	angina
#29	AnnotatorNotes T38	C0002962; Angina Pectoris; Sign or Symptom
T39	DISO 1745 1767	insuficiencia cardiaca
#30	AnnotatorNotes T39	C0018801; Heart failure; Disease or Syndrome
T40	DISO 1769 1793	síndrome coronario agudo
#31	AnnotatorNotes T40	C0948089; Acute Coronary Syndrome; Disease or Syndrome
T41	DISO 1806 1848	Enfermedad neurológica o neuropsiquiátrica
T42	DISO 1855 1863	síntomas
#32	AnnotatorNotes T42	C1457887; Symptoms; Sign or Symptom
T43	PROC 1891 1933	evaluación de la seguridad y tolerabilidad
T44	DISO 1937 1971	Abuso activo de alcohol y/o drogas
T45	CHEM 227 242	antirretroviral
#33	AnnotatorNotes T45	C0599685; Anti-Retroviral Agents; Pharmacologic Substance
T46	CHEM 369 384	antirretroviral
#34	AnnotatorNotes T46	C0599685; Anti-Retroviral Agents; Pharmacologic Substance
T47	CHEM 474 489	antirretroviral
#35	AnnotatorNotes T47	C0599685; Anti-Retroviral Agents; Pharmacologic Substance
T48	ANAT 766 773	células
#36	AnnotatorNotes T48	C0007634; Cells; Cell | C1269647; Entire cell; Cell
T49	CHEM 579 594	antirretroviral
#37	AnnotatorNotes T49	C0599685; Anti-Retroviral Agents; Pharmacologic Substance
T50	DISO 909 934	mutaciones de resistencia
T51	PROC 1117 1124	tratada
#38	AnnotatorNotes T51	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T52	ANAT 1151 1157	portal
#39	AnnotatorNotes T52	C0032718; Portal vein structure; Body Part, Organ, or Organ Component | C1305775; Entire portal vein; Body Part, Organ, or Organ Component
T53	CHEM 1266 1276	esteroides
#40	AnnotatorNotes T53	C0038317; Steroids; Organic Chemical · Pharmacologic Substance
T54	CHEM 1278 1295	inmunomoduladores
#41	AnnotatorNotes T54	C1527392; Immunomodulators; Immunologic Factor · Pharmacologic Substance
T55	DISO 1397 1425	interacciones farmacológicas
T56	PROC 1521 1556	Aclaramiento estimado de creatinina
T57	DISO 1623 1646	virus de la hepatitis B
T58	ANAT 1713 1727	cardiovascular
#42	AnnotatorNotes T58	C0007226; Cardiovascular system; Body System | C3887460; Cardiovascular; Body Location or Region
T59	ANAT 1759 1767	cardiaca
#43	AnnotatorNotes T59	C0018787; Heart; Body Part, Organ, or Organ Component | C1281570; Entire heart; Body Part, Organ, or Organ Component
T60	ANAT 1778 1787	coronario
#44	AnnotatorNotes T60	C0205042; Coronary artery; Body Part, Organ, or Organ Component + C1269008; Entire coronary artery; Body Part, Organ, or Organ Component
T61	CHEM 2088 2096	fármacos
#45	AnnotatorNotes T61	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T62	Date 13 17	2018
T63	LIVB 178 186	personas
#46	AnnotatorNotes T63	C0027361; Persons; Population Group
T64	Neg_cue 211 214	sin
T65	PHYS 403 411	curación
#47	AnnotatorNotes T65	C2004454; Recovery - healing process; Organism Function
T66	LIVB 425 433	personas
#48	AnnotatorNotes T66	C0027361; Persons; Population Group
T67	Neg_cue 458 461	sin
T68	LIVB 521 538	Pacientes adultos
#49	AnnotatorNotes T68	C0030705; Patients; Patient or Disabled Group + C0001675; Adult; Age Group
T70	LIVB 557 560	VIH
#50	AnnotatorNotes T70	C0019682; HIV; Virus
T71	Neg_cue 563 566	sin
T72	LIVB 631 640	Pacientes
#51	AnnotatorNotes T72	C0030705; Patients; Patient or Disabled Group
T73	Age 675 690	≥ 18 y <65 años
T75	PHYS 1023 1031	Embarazo
#52	AnnotatorNotes T75	C0032961; Pregnancy; Organism Function
T76	LIVB 1059 1086	virus B o C de la hepatitis
#53	AnnotatorNotes T76	C0019169; hepatitis B virus; Virus | C0220847; hepatitis C virus; Virus
T77	Neg_cue 1114 1116	no
T78	Date 1215 1222	pasadas
T79	Date 1225 1233	actuales
T85	Duration 1656 1667	dos semanas
T86	Date 1794 1802	reciente
T88	LIVB 2032 2044	investigador
#54	AnnotatorNotes T88	C0035173; Research Personnel; Professional or Occupational Group
T69	LIVB 662 667	VIH-1
#55	AnnotatorNotes T69	C0019704; HIV-1; Virus
T84	LIVB 732 737	VIH-1
#56	AnnotatorNotes T84	C0019704; HIV-1; Virus
T74	LIVB 205 210	VIH-1
#57	AnnotatorNotes T74	C0019704; HIV-1; Virus
T80	LIVB 452 457	VIH-1
#58	AnnotatorNotes T80	C0019704; HIV-1; Virus
T81	CHEM 1965 1971	drogas
#59	AnnotatorNotes T81	C0086190; Illicit Drugs; Hazardous or Poisonous Substance
T82	PROC 728 737	ARN VIH-1
#60	AnnotatorNotes T82	C1294179; HIV 1 RNA assay; Laboratory Procedure
A1	Assertion T6 Negated
A2	Assertion T12 Negated
A3	Population_data T68 Age
A4	Assertion T14 Negated
A5	Assertion T51 Negated
A6	Status T12 History_of
A7	Status T14 History_of
A8	Status T35 History_of
A9	Status T47 History_of
A10	Status T49 History_of
A11	Status T29 History_of
#61	AnnotatorNotes T1	C0511730; Identify product efficacy and safety issues; Health Care Activity
#62	AnnotatorNotes T8	C0511730; Identify product efficacy and safety issues; Health Care Activity
#63	AnnotatorNotes T4	C1963724; Antiretroviral therapy; Therapeutic or Preventive Procedure
#64	AnnotatorNotes T5	C2363741; HIV-1 infection; Disease or Syndrome
#65	AnnotatorNotes T11	C2363741; HIV-1 infection; Disease or Syndrome
#66	AnnotatorNotes T15	C2363741; HIV-1 infection; Disease or Syndrome
#67	AnnotatorNotes T57	C0019163; Hepatitis B; Disease or Syndrome
#68	AnnotatorNotes T43	C3274448; Tolerability Study; Research Activity + C1705187; Safety Study; Research Activity
#69	AnnotatorNotes T79	C0521116; Current (present time); Temporal Concept 
#70	AnnotatorNotes T25	C1609538; Latent Tuberculosis; Disease or Syndrome 
#71	AnnotatorNotes T55	C0687133; Drug Interactions; Pathologic Function
#72	AnnotatorNotes T56	C1273051; Estimated creatinine clearance; Laboratory Procedure 
#73	AnnotatorNotes T44	C0085762; Alcohol abuse; Mental or Behavioral Dysfunction + C0013146; Drug abuse; Mental or Behavioral Dysfunction
#74	AnnotatorNotes T78	C1444637; In the past; Temporal Concept
#75	AnnotatorNotes T86	C0332185; Recent; Temporal Concept
T83	Spec_cue 1864 1872	pudieran
T87	CONC 1873 1883	interferir
A12	Assertion T87 Speculated
#76	AnnotatorNotes T87	C0521102; Interferes with; Functional Concept
T89	Spec_cue 2046 2053	pudiera
T90	CONC 2054 2064	interferir
A13	Assertion T90 Speculated
#77	AnnotatorNotes T90	C0521102; Interferes with; Functional Concept
T91	Observation 2071 2096	adherencia a los fármacos
#78	AnnotatorNotes T91	C2364172; Adherence To Medication Regime; Finding
R1	Speculation Arg1:T89 Arg2:T90	
T92	Food 1953 1960	alcohol
#79	AnnotatorNotes T92	C0001967; Alcoholic Beverages; Food
R2	Combined_with Arg1:T3 Arg2:T4	
R3	Used_for Arg1:T2 Arg2:T4	
R4	Experiences Arg1:T63 Arg2:T5	
R5	Causes Arg1:T74 Arg2:T5	
R6	Experiences Arg1:T63 Arg2:T3	
R7	Negation Arg1:T64 Arg2:T6	
R8	Used_for Arg1:T45 Arg2:T6	
R9	Experiences Arg1:T63 Arg2:T6	
R10	Combined_with Arg1:T9 Arg2:T10	
R11	Used_for Arg1:T46 Arg2:T10	
R12	Experiences Arg1:T66 Arg2:T65	
R13	Causes Arg1:T80 Arg2:T11	
R14	Negation Arg1:T67 Arg2:T12	
R15	Used_for Arg1:T47 Arg2:T12	
R16	Experiences Arg1:T66 Arg2:T11	
R17	Experiences Arg1:T66 Arg2:T9	
R18	Causes Arg1:T70 Arg2:T13	
R19	Experiences Arg1:T68 Arg2:T13	
R20	Experiences Arg1:T68 Arg2:T14	
R21	Used_for Arg1:T49 Arg2:T14	
R22	Negation Arg1:T71 Arg2:T14	
R23	Experiences Arg1:T72 Arg2:T15	
R24	Causes Arg1:T69 Arg2:T15	
R25	Has_Age Arg1:T72 Arg2:T73	
T93	Result_or_Value 714 727	>1x104 copias
T95	Result_or_Value 761 776	>350 células/μL
R28	Has_Result_or_Value Arg1:T19 Arg2:T95	
T96	Quantifier_or_Qualifier 801 810	analítica
R29	Has_Quantifier_or_Qualifier Arg1:T20 Arg2:T96	
T97	Quantifier_or_Qualifier 935 942	mayores
R30	Has_Quantifier_or_Qualifier Arg1:T50 Arg2:T97	
T98	Quantifier_or_Qualifier 1012 1019	activas
#80	AnnotatorNotes T98	C0679217; Active State; Idea or Concept
R31	Has_Quantifier_or_Qualifier Arg1:T23 Arg2:T98	
R32	Causes Arg1:T76 Arg2:T24	
R33	Negation Arg1:T77 Arg2:T51	
R34	Location_of Arg1:T52 Arg2:T27	
R35	Overlap Arg1:T29 Arg2:T78	
R36	Overlap Arg1:T29 Arg2:T79	
R37	Used_for Arg1:T53 Arg2:T30	
R38	Used_for Arg1:T54 Arg2:T30	
T99	Observation 1315 1339	Anomalías de laboratorio
#81	AnnotatorNotes T99	C3648370; laboratory tests nonspecific abnormal findings; Finding
T100	Quantifier_or_Qualifier 1340 1351	grado 3 o 4
R39	Has_Quantifier_or_Qualifier Arg1:T99 Arg2:T100	
T101	Quantifier_or_Qualifier 1368 1380	concomitante
#82	AnnotatorNotes T101	C0521115; Simultaneous; Temporal Concept
R40	Has_Quantifier_or_Qualifier Arg1:T32 Arg2:T101	
R41	Causes Arg1:T32 Arg2:T55	
R42	Causes Arg1:T33 Arg2:T55	
T102	Result_or_Value 1557 1566	<50ml/min
R43	Has_Result_or_Value Arg1:T56 Arg2:T102	
R44	Overlap Arg1:T35 Arg2:T85	
T103	CONC 1678 1698	comienzo del estudio
#83	AnnotatorNotes T103	C4684789; Study Start; Temporal Concept
R45	Before Arg1:T35 Arg2:T103	
R46	Location_of Arg1:T58 Arg2:T37	
R47	Location_of Arg1:T59 Arg2:T39	
R48	Overlap Arg1:T40 Arg2:T86	
R49	Location_of Arg1:T60 Arg2:T40	
R50	Speculation Arg1:T83 Arg2:T87	
R51	Causes Arg1:T41 Arg2:T42	
R53	Causes Arg1:T92 Arg2:T44	
R54	Causes Arg1:T81 Arg2:T44	
R57	Causes Arg1:T9 Arg2:T65	
T104	Quantifier_or_Qualifier 412 421	funcional
#84	AnnotatorNotes T104	C0205245; Functional; Functional Concept 
R58	Has_Quantifier_or_Qualifier Arg1:T65 Arg2:T104	
T105	Quantifier_or_Qualifier 1426 1433	mayores
#85	AnnotatorNotes T105	C0205164; Major; Qualitative Concept
R59	Has_Quantifier_or_Qualifier Arg1:T55 Arg2:T105	
R26	Has_Result_or_Value Arg1:T82 Arg2:T93	
R71	Causes Arg1:T84 Arg2:T16	
R27	Combined_with Arg1:T32 Arg2:T33	
R60	Overlap Arg1:T91 Arg2:T61	
#86	AnnotatorNotes T2	C0599685; Anti-Retroviral Agents; Pharmacologic Substance
#87	AnnotatorNotes T41	C0006111; Brain Diseases; Disease or Syndrome | C0004936; Mental disorders; Mental or Behavioral Dysfunction (?)
#88	AnnotatorNotes T97	C0205164; Major; Qualitative Concept
R55	Experiences Arg1:T66 Arg2:T12	
#89	AnnotatorNotes T50	C5704646; Drug resistance mutation; Cell or Molecular Dysfunction
A14	Experiencer T88 Other
A15	Experiencer T63 Patient
A16	Experiencer T66 Patient
A17	Experiencer T68 Patient
A18	Experiencer T72 Patient
